Last reviewed · How we verify

PERICAPSULAR NERVE BLOCK

Sahiwal medical college sahiwal · FDA-approved active Small molecule Quality 2/100

Pericapsular Nerve Block is a marketed product developed by Sahiwal Medical College Sahiwal, with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that may offer a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic namePERICAPSULAR NERVE BLOCK
Also known asPENG
SponsorSahiwal medical college sahiwal
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: